首页> 外文期刊>Cancer: A Journal of the American Cancer Society >Nonrandomized comparison of neurofibromatosis type 1 and non-neurofibromatosis type 1 children who received carboplatin and vincristine for progressive low-grade glioma: A report from the Children's Oncology Group
【24h】

Nonrandomized comparison of neurofibromatosis type 1 and non-neurofibromatosis type 1 children who received carboplatin and vincristine for progressive low-grade glioma: A report from the Children's Oncology Group

机译:非萌芽的神经纤维素病1型和非神经纤维瘤病的比较1型接受Carboplatin和渐进式低级胶质瘤的儿童:儿童肿瘤组的报告

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUNDTo evaluate tumor responses, event-free survival (EFS), overall survival (OS), and toxicity of chemotherapy, children with neurofibromatosis type 1 (NF1) and progressive low-grade glioma were enrolled into the Children's Oncology Group (COG) A9952 protocol and treated with carboplatin and vincristine (CV).
机译:背景技术评估肿瘤反应,无事实存活(EFS),整体存活(OS)和化疗的毒性,患有神经纤维瘤病的儿童(NF1)和渐进低级胶质瘤的儿童注册到儿童肿瘤组(COG)A9952协议中 并用卡铂和长春克拉汀(CV)治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号